美国FDA 指导原则 改善临床试验中未被充分代表的种族和民族人口的参与者的多样性计划；行业指南草案；可获得性行业指南草案 英文原版.pdfVIP

Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry DRAFT G UIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to . Submit written comments to t